The chart below shows how SYRS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SYRS sees a +1.71% change in stock price 10 days leading up to the earnings, and a -17.11% change 10 days following the report. On the earnings day itself, the stock moves by -0.24%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Market Opportunity for MDS Therapeutics: 1. Significant Market Opportunity: The total market opportunity for higher-risk MDS therapeutics in the U.S. is projected to reach approximately $1.6 billion by 2029, with tamibarotene alone expected to capture over $800 million for patients with RARA overexpression.
R&D Expense Reduction: 2. Reduced R&D Expenses: R&D expenses decreased to $20.5 million in Q3 2024 from $28.3 million in Q3 2023, reflecting a focused investment strategy on advancing tamibarotene.
Cost Management Success: 3. Lower General & Administrative Expenses: G&A expenses were reduced to $5.7 million in Q3 2024 compared to $7.8 million in Q3 2023, indicating effective cost management measures.
Net Loss Improvement: 4. Improved Net Loss: The net loss for Q3 2024 was $6.4 million, or $0.16 per share, significantly improved from a net loss of $40.1 million, or $1.43 per share, in the same period last year.
Cash Reserves Stability: 5. Strong Cash Position: As of September 30, 2024, cash and cash equivalents stood at $58.3 million, sufficient to fund anticipated operating expenses into the third quarter of 2025.
Negative
Revenue Decline Analysis: 1. No Revenue Recognition: Syros Pharmaceuticals reported no revenue in Q3 2024, a significant decline from $3.8 million in Q3 2023, attributed to the termination of their collaboration agreement with Pfizer.
Net Loss Improvement: 2. Increased Net Loss: The company reported a net loss of $6.4 million, or $0.16 per share, in Q3 2024, which, while improved from a net loss of $40.1 million, or $1.43 per share, in Q3 2023, still indicates ongoing financial challenges.
Cash Position Decline: 3. Decreased Cash Position: Cash and cash equivalents decreased to $58.3 million as of September 30, 2024, down from $79 million as of June 30, 2024, raising concerns about the company's liquidity.
R&D Expense Reduction: 4. Reduced R&D Spending: R&D expenses fell to $20.5 million in Q3 2024 from $28.3 million in Q3 2023, reflecting a cutback in external R&D and consulting, which may impact future product development.
Sustained Financial Losses: 5. Ongoing Financial Losses: Despite a reduction in losses, the company continues to operate at a loss, indicating potential sustainability issues as they prepare for the launch of tamibarotene.
Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript
SYRS.O
-7.14%